SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as President Trump's threats of new tariffs on European nations over Greenland escalate geopolitical tensions, leading to a risk-off market sentiment. The community is divided, with some anticipating a significant market pullback, while others view it as a 'buy the dip' opportunity, also noting a Japan-led bond sell-off as a contributing factor. This environment is fueling discussions about broader market volatility and a flight to safe-haven assets.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following constructive discussions with the FDA regarding a resubmission path for ANKTIVA in bladder cancer, complemented by significant international approvals and strategic partnerships like those recently established in Saudi Arabia for broader cancer indications. This development, coupled with high short interest, is fueling widespread community excitement about a potential paradigm shift in oncology and intense speculation regarding a short squeeze amidst growing calls for expedited access to these innovative treatments.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is actively trending amid escalating US-EU trade tensions driven by President Trump's tariff threats over Greenland, sparking a widespread market sell-off and global risk-off sentiment. The investment community is sharply divided between those anticipating a deeper correction for technology and growth stocks and fervent "buy the dip" proponents. Immediate market focus remains on an upcoming Supreme Court ruling regarding tariff authority and a heavy week of earnings reports, amplifying uncertainty.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is a major talking point following its J.P. Morgan conference appearance, where investors are eagerly seeking clarity on its strategy for advancing the Matrix-M adjuvant technology and securing new collaborations. Community sentiment is sharply focused on management's pace in realizing pipeline potential, including a recent Pfizer agreement and ongoing Sanofi ventures, with an activist investor's growing stake and significant short interest adding to the intense market watch.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending after announcing positive data from its placebo-controlled Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing strong efficacy. The community is actively discussing the oral ITK inhibitor's potential in a large market, with many anticipating significant revaluation and partnership opportunities for its novel mechanism of action.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is gaining significant attention as its patented Optical Interposer platform is seen as crucial for next-generation AI and data center infrastructure, enabling highly efficient and scalable optical interconnects. The community is actively discussing recent product innovation awards and confirmed partnerships, including with Celestial AI (now Marvell), which validate its technology. Anticipation is also building for the imminent disclosure of major institutional investors, signaling strong long-term confidence.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid intense debate surrounding the Federal Reserve's independence, fueled by a federal probe into its Chair and the administration's aggressive policy maneuvers impacting bond markets. Investors are actively discussing whether long-term treasuries offer a crucial hedge against a potential economic slowdown or face further headwinds from escalating national debt and geopolitical uncertainty.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is actively trending amid recent allegations of money laundering and illicit financial ties, triggering a sharp sell-off across the stock. Despite this, community sentiment is divided, with many dismissing the claims as a coordinated short attack ahead of strong earnings, while others are seizing the opportunity to buy into the fundamentally strong AI-powered ad platform.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is seeing heightened conversation due to recent developments surrounding Trump's assertive stance on Greenland and reactions to a perceived Nobel Peace Prize snub, which has sparked discussions of new tariffs on European nations. The community is actively debating the potential for increased market volatility, geopolitical instability, and the broader economic ramifications of these actions. This ongoing dialogue underscores intense political polarization and its influence on market sentiment.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is trending strongly as renewed geopolitical tensions, including recent tariff threats concerning European countries over Greenland, fuel a broad flight to safety. The community views gold as a crucial hedge against eroding fiat currency confidence and economic instability, driving prices to consistent new highs. Many are discussing significant further appreciation as these global uncertainties persist.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tango Therapeutics (NASDAQ:TNGX) Sets New 52-Week High - Here's Why

Tango Therapeutics (NASDAQ:TNGX) Hits New 12-Month High - What's Next...

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm, Marketbeat.com...

Tango Therapeutics (NASDAQ:TNGX) Trading 8.3% Higher - Should You Buy?

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 8.3% - Here's What Happened...

Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 8.4% - What's Next?

Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 8.4% - What's Next...

Tango Therapeutics (NASDAQ:TNGX) Sees Large Volume Increase - Should You Buy?

Tango Therapeutics (NASDAQ:TNGX) Sees Unusually-High Trading Volume - Here's What Happened...

3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 

EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well. 

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the stock, Marketbeat reports...

5 Biotech Stocks to Watch for Potential Upside

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector. 

Tango Therapeutics (NASDAQ:TNGX) Raised to Buy at Wall Street Zen

Wall Street Zen raised Tango Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday...

Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance

Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance PR Newswire VANCOUVER, BC, Dec. 12, 2025 Issued on behalf...

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Current Price	$13.01
Prev Close	$11.69
Open	$11.48
Dividend Yield	0.00%
50-Day Moving Average	$9.40
Beta	1.21
Avg. Volume	2.54M
PE Ratio	-14.20

52-Week High	$13.18
52-Week Low	$1.03
Market Capitalization	$1.75B
EPS (Annual)	-$1.19
Price to Book	9.07
Revenue Per Employee	$271,412.90
Enterprise Value/EBITDA	N/A

TNGX
Tango Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNGX News

TNGXTango Therapeutics Inc